nach oben

Journal of General Internal Medicine

Erschienen in:

01.02.2014 | Review Article

Pitfalls in Hemoglobin A1c Measurement: When Results may be Misleading

verfasst von: Michael S. Radin, MD, FACE

Erschienen in: Journal of General Internal Medicine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

ABSTRACT

Since the beginning of clinical use in the 1970s, hemoglobin A1c (A1c) has become the standard tool for monitoring glycemic control in patients with diabetes. The role of the A1c test was broadened in 2010, when the American Diabetes Association added A1c as a diagnostic criterion for diabetes. Because of hemoglobin A1c’s integral role in diagnosis and treatment, it is important to recognize clinical scenarios and interfering factors that yield false results. The purpose of this review is to describe the A1c measurement, outline clinical scenarios or factors that may yield false results, and describe alternative laboratory biomarkers.

Sacks DB. Measurement of Hemoglobin A1c. Diabetes Care. 2012;35:2674–80.PubMedCrossRef

Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem. 2011;57(2):205–14.PubMedCrossRef

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl. 1):S62–9.CrossRef

International Expert Committee. International Expert Committee report on the role of A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.CrossRef

Steinberg MH, Benz EJ Jr, Adewoye AH, Ebert BL. Hemoglobin synthesis, structure, and function. In: Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2009. Chap 33.

Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of hemoglobin A1c: slow glycosylation of hemoglobin in vitro. J Clin Invest. 1976;57:1652–9.PubMedCentralPubMedCrossRef

Saudek CD, Brick JC. Clinical advances in hemoglobin A1c measurement: the clinical use of hemoglobin A1c. J Diabetes Sci Technol. 2009;3(4):629–34.PubMedCentralPubMedCrossRef

Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440–7.PubMedCrossRef

Nathan DM, Kuenen J, Borg R, et al. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–8.PubMedCrossRef

10.

Homa K, Majkowska L. Difficulties in interpreting HbA1c results. Pol Arch Med Wewn. 2010;120:148–54.PubMed

11.

Little RR, Roberts WL. Laboratory advances in hemoglobin A1c measurement: a review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3(3):446–51.PubMedCentralPubMedCrossRef

12.

Chang A, Frank J, Knaebel J, Fullam J, Pardo S, Simmons DA. Evaluation of an over-the-counter glycated hemoglobin (A1c) test kit. J Diabetes Sci Technol. 2010;4(6):1495–503.PubMedCentralPubMedCrossRef

13.

Al-Ansary L, Farmer A, Hirst J, et al. Point-of-care testing for HbA1c in the management of diabetes: a systematic review and metaanalysis. Clin Chem. 2011;57(4):568–76.PubMedCrossRef

14.

Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010;56:44–52.PubMedCrossRef

15.

Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: Implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97(4):1067–72.PubMedCrossRef

16.

Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet. 1980;2:141.PubMedCrossRef

17.

Tarim O, Küçükerdoğan A, Günay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int. 1999;41:357–62.PubMed

18.

Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 2004;112:126–8.PubMedCrossRef

19.

Nitin S. HbA1c and factors other than diabetes mellitus affecting it. Singap Med J. 2010;51:616–22.

20.

Arnold JG, McGowan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1c levels. J Am Board Fam Med. 2007;20:93–6.PubMedCrossRef

21.

Larese J. When is hemoglobin A1c inaccurate in assessing glycemic control? NYU Langone Internal Medicine Blog, Faculty Peer Reviewed. http://www.clinicalcorrelations.org/?p=5190. Updated February, 2012. Accessed August 2013.

22.

Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011;57(2):344–6.PubMedCrossRef

23.

Falko JM, O’Dorisio TM, Cataland S. Spurious elevations in glycosylated hemoglobin (HbA1) secondary to hypertriglyceridemia. Arch Intern Med. 1982;142(7):1370–1.PubMedCrossRef

24.

HbA1c assay interferences. National Glycohemoglobin Standardization Program Web site. Available at: http://www.ngsp.org/interf.asp. Updated August, 2012. Accessed August 2013.

25.

Hoberman HD, Chiodo SM. Elevation of the hemoglobin A1 fraction in alcoholism. Alcohol Clin Exp Res. 1982;6(2):260–6.PubMedCrossRef

26.

Hazelette SE, Liebelt RA, Brown WJ, Androulakakis V, Jarjoura D, Truitt EB Jr. Evaluation of acetaldehyde-modified hemoglobin and other markers of chronic heavy alcohol use: effects of gender and hemoglobin concentration. Alcohol Clin Exp Res. 1998;22(8):1813–9.

27.

Rastelli G, Gerra G, Mineo F, et al. Homeostasis of blood glucose and abuse of exogenous opiates: evaluation of fructosamine and glycosylated hemoglobin. Minerva Med. 1987;78(17):1291–6.PubMed

28.

Tran HA, Silva D, Petrovsky N. Case study: potential pitfalls of using hemoglobin A1c as the sole measure of glycemic control. Clin Diabetes. 2004;22(3):141–3.CrossRef

29.

Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation of proteins. Diabetes. 1992;41(2):167–73.PubMedCrossRef

30.

Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int. 2010;30:72–9.PubMedCrossRef

31.

Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39(2):297–307.PubMedCrossRef

32.

Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000;93(2):185–92.PubMedCrossRef

33.

Lind T, Cheyne GA. Effect of normal pregnancy upon glycosylated haemoglobins. Br J Obstet Gynaecol. 1979;86:210–3.PubMedCrossRef

34.

Hanson U, Hagenfeldt L, Hagenfeldt K. Glycosylated hemoglobins in normal pregnancy: sequential changes and relation to birth weight. Obstet Gynecol. 1983;62:741–4.PubMed

35.

Phelps RL, Honig GR, Green D, Metzger BE, Frederiksen MC, Freinkel N. Biphasic changes in hemoglobin A1c concentrations during normal human pregnancy. Am J Obstet Gynecol. 1983;147:651–3.PubMed

36.

Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetes complications? Diabetes Care. 1991;14(1):68–72.PubMedCrossRef

37.

Gross BN, Cross LB, Foard JC, Wood YA. Falsely low hemoglobin A1c levels in a patient receiving ribavirin and peginterferon alpha-2b for hepatitis C. Pharmacotherapy. 2009;29(1):121–3.PubMedCrossRef

38.

Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N. Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepat. 2006;13(9):613–7.PubMedCrossRef

39.

Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153–63.PubMed

40.

Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care. 2000;23:339–44.PubMedCrossRef

41.

Sacks DB. A1c versus glucose testing: a comparison. Diabetes Care. 2011;34(2):518–23.PubMedCrossRef

42.

Smaldone A. Glycemic control and hemoglobinopathy: when A1c may not be reliable. Diabetes Spectrum. 2008;21:46–9.CrossRef

43.

Ambruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem. 1987;33(12):2153–63.

44.

Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, Sacks DB. Tests of glycemia in diabetes. Diabetes Care. 2004;27(7):1761–73.PubMedCrossRef

45.

Chen HS, Wu TE, Lin HD, et al. Hemoglobin A1c and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010;55:867–74.PubMedCrossRef

46.

Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062–8.PubMedCrossRef

47.

Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903.PubMedCrossRef

48.

Beck R, Steffes M, Xing D, et al. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes. 2011;12(8):690–5.PubMedCentralPubMedCrossRef

49.

Dungan KM. 1,5-anhydroglucitol (GlycoMark^TM) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9–19.PubMedCrossRef

50.

McGill JB, Cole TJ, Nowatzke W, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia. Diabetes Care. 2004;27:1859–65.PubMedCrossRef

51.

Nielsen JK. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diabetes Sci Technol. 2007;1(6):857–63.PubMedCentralPubMedCrossRef

52.

Vaddiraju S, Burgess DJ, Tomazos I, Jain FC, Papadimitrakopoulos F. Technologies for continuous glucose monitoring: current problems and future promises. J Diabetes Sci Technol. 2010;4(6):1540–62.PubMedCentralPubMedCrossRef

53.

Lucarelli F, Ricci F, Caprio F, et al. GlucoMen Day continuous glucose monitoring system: a screening for enzymatic and electrochemical interferents. J Diabetes Sci Technol. 2012;6(5):1172–81.PubMedCentralPubMedCrossRef

54.

Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(10):2968–79.PubMedCrossRef

Titel: Pitfalls in Hemoglobin A1c Measurement: When Results may be Misleading
verfasst von: Michael S. Radin, MD, FACE
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of General Internal Medicine / Ausgabe 2/2014
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-013-2595-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

ABSTRACT

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Complementary Medicine

Janet’s Prayer

Non-Traditional Risk Factors are Important Contributors to the Racial Disparity in Diabetes Risk: The Atherosclerosis Risk in Communities Study

Embolization of Hemorrhaging Rectus Sheath Hematoma

Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes